Tranzyme Pharma

Publications & Posters

Title	Date	Size
TZP-102 Ghrelin Receptor Agonist Improves Symptoms of Diabetic Gastroparesis in Both Type 1 and Type 2 Diabetic Patients	ADA 2012	166.2 KB
Tranzyme Pharma, Developing a New Drug for Treatment of Diabetic Gastroparesis	ASweetLife 2012	N/A
TZP-102 Ghrelin Agonist Improves Symptoms of Gastroparesis in Both Type 1 and Type 2 Diabetic Patients: a 28-Day Treatment Study Data	Neurodiab 2011	400.9 KB
TZP-102, Ghrelin Agonist Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated With Patient Rating of Overall Treatment Effect	DDW 2011	170.3 KB
Orally Administered Ghrelin Agonist TZP-102 Decreases Overall Severity of Symptoms of Diabetic Gastroparesis	ACG 2010	920.6 KB
From Libraries of Small Molecule Macrocycles to Drugs	DDC 2009	348.1 KB
The motilin receptor antagonist TZP-201 is highly effective in the control of irinotecan induced diarrhea in beagle dogs	AACR 2007	115.5 KB

= add file to Briefcase